Trials / Recruiting
RecruitingNCT07304128
A Study of PLB-002 in Advanced Solid Tumors
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Primelink BioTherapeitics(ShenZhen) Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLB-002 | antibody drug conjugate (ADC) |
Timeline
- Start date
- 2026-02-06
- Primary completion
- 2027-06-30
- Completion
- 2027-12-30
- First posted
- 2025-12-26
- Last updated
- 2026-03-03
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07304128. Inclusion in this directory is not an endorsement.